HutchMed/AstraZeneca Approved to Launch Partnered MET Inhibitor in China

HutchMed and AstraZeneca report their MET tyrosine kinase inhibitor was granted conditional China approval for patients with a rare form of NSCLC. Orpathys (savolitinib) was approved as a second-line treatment for NSCLC with MET exon 14 skipping alterations. For those who are unable to receive chemotherapy, it will be a first-line therapy. Approximately 2-3% of NSCLC patients have MET exon 14 skipping alterations, a targetable mutation in the MET gene. It is the first approval for savolitinib, which HutchMed partnered with AstraZeneca ten years ago. More details.... Stock Symbols: (NSDQ/AIM: HMP) (NYSE: AZM) Share this with colleagues: // //